Navigation Links
Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation
Date:7/29/2008

est and longest placebo-controlled AD treatment trial ever completed," Green said. "While the trial did not meet its endpoints, it was well-designed and executed, and it provided clear answers regarding Flurizan's lack of efficacy and its safety."

"The fact that both the drug-treated and placebo groups declined over the course of the trial - and that the placebo-treated patients declined at the expected rate - shows that we can do this type of trial in people with mild Alzheimer's. As the first trial to ever study a large population of mild Alzheimer's patients, we've collected very valuable data on the progression of the disease in its earliest stages. We are confident that the results of this study will help researchers in their quest to develop new and better treatments for Alzheimer's," Green added.

"This drug candidate, in this dose, in this group did not work. But, like much good science, the study raises as many questions as it does provide answers. Was the dose right? Was the study long enough? Did they start the intervention early enough in the course of the disease? Designing and executing clinical studies that answer these questions will help us defeat Alzheimer's disease," Gandy said. "The only way we are going to solve the problem of Alzheimer's is for scientists and companies to have the courage to make significant investments in these large scale trials - which may or may not work. This was a very well done study and the company and scientists are to be commended for that."

Phase IIa Trial of PBT2, a Metal-Protein Attenuating Compound, in Mild Alzheimer's

PBT2 is a metal-protein attenuating compound (MPAC) being developed by Prana Biotechnology as a potential Alzheimer's therapy. In previous research, ions of copper and zinc were found to play a role in the aggregation of beta amyloid protein, which is believed to cause functional damage in Alzheimer's. According to Prana, PBT2 reduces the toxic form of beta amyloid by prev
'/>"/>

SOURCE Alzheimer's Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
5. Controversy About Lack of Placebo Group Decline in Alzheimers Clinical Trials
6. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
7. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
8. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
9. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
10. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
11. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... the "US Self-monitoring Blood Glucose Market" report ... This market insight focuses on the ... the United States . Reimbursement analysis and ... product analyses for more than 73 SMBG meters have ...
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held medical ... has been appointed Interim Chief Executive Officer of the ... succeeds Ken Berger .  "The Board of Directors ... leading ConvaTec over the past three years," said ... Directors.  "We are confident that the company is well ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... issued the following open letter to shareholders from ... Med. Sc. Dear RXi Shareholders, ... of inaccurate statements posted on certain social media ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... of Novel Proteasome Inhibitor in ... Patients with Relapsed Solid Tumors, SOUTH SAN ... South Texas Accelerated Research Therapeutics (START),today announced the enrollment of ... Proteolix,s investigational drug, carfilzomib (PR-171).,START is participating in the study ...
... Protects the Ocular Surface Following Exposure to ... Dry Eye Symptoms, LAGUNA HILLS, Calif., Oct. 9 ... ALTY-0501, demonstrated statistically,significant advantages over vehicle in its ability ... Phase 2 study. The Phase 2 study utilized ...
Cached Medicine Technology:Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors 2Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors 3Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 2Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 3
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... Thousands of transvaginal mesh lawsuits ( ... number of multidistrict litigations currently underway in U.S. District ... reports. According to an Order issued on December 2, ... Status Conference in all of the proceedings on January ... to submit a proposed agenda to the Court by ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 Each ... visits and 2 million hospital admissions across the nation ... Prevention ). The CDC’s National Hospital Ambulatory Medical ... through a survey conducted in 2010. They estimated that ... visits that resulted in a primary diagnosis of broken ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... Health plan members who individually purchase their plans ... satisfied with their health plan experience, compared with ... according to the J.D. Power and Associates 2009 ... today.(Logo: http://www.newscom.com/cgi-bin/prnh/20050527/LAF028LOGO-a )Now in its third ...
... with Allen Cardoza , Los Angeles, California, April ... 2 Our special guest this week is Dr. ... practice. Shelly has been a coach and presenter to ... as a Doctor of Psychology and a Licensed Marriage ...
... found in all living cells could serve as a ... or nicotinamide adenine dinucleotide, is a key coenzyme -- ... enzyme -- found mostly in the inner membrane of ... series of biochemical reactions that involve various enzymes to ...
... on how a small hospital improved charge capture ... day using Craneware,s Bill AnalyzerATLANTA, April 2 ... provider of financial performance solutions, announced today it ... Hospital at the annual conference of the Healthcare ...
... (formerly Diagnostic Ultrasound Corporation) an innovator in medical ... care providers, is celebrating its 25th anniversary this ... 2, 1984 founding in a modest basement workshop, ... with the company,s products now used by health ...
... is a statement from Jeff Levi, PhD, Executive Director of ... of the new report Beyond Health Care: Directions to ... Commission to Build a Healthier America:"Every American should have the ... be. And every community should be safe from threats ...
Cached Medicine News:Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 2Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 3Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 4Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 5Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 6Health News:Naturally fluorescent molecules may serve as cancer biomarker 2Health News:Naturally fluorescent molecules may serve as cancer biomarker 3Health News:Craneware and St. Joseph to Present Revenue Enhancement Success Story at HIMSS 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Celebrates 25 Years of Improving Patient Care 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Celebrates 25 Years of Improving Patient Care 3Health News:Trust for America's Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America 2Health News:Trust for America's Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America 3
Inquire...
... new QIAvac 24 Plus vacuum manifold allows processing of ... tedious loading and unloading of spin columns into and ... Plus offers: Time savings ... DNA, PCR products, and RNA Convenience ...
... Kuderna-Danish, Rotary, Vacuum-Style and Nitrogen Blow-Down Evaporators. For over ten years TurboVap concentration technology has received enormous ... ... ... ...
... The UltraVac manifold is designed ... The manifold holds one deep ... Samples and buffers are drawn through ... collection plates or microplates. The ...
Medicine Products: